Anthracenedione-methionine conjugates are novel topoisomerase II-targeting anticancer agents with favorable drug resistance profiles

Biochemical Pharmacology

Volumn 83, Issue 9, 2012, Pages 1208-1216

  Lee, Chieh Hua ^a   Hsieh, Mei Yi ^a   Hsin, Ling Wei ^a   Chen, Hsiang Chin ^a   Lo, Su Chi ^a   Fan, Jia Rong ^a   Chen, Wan Ru ^a   Chen, Hung Wei ^a   Chan, Nei Li ^a   Li, Tsai Kun ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Anthracenedione; Cleavable complex; Mitoxantrone; Multi drug resistance; Topoisomerase

Indexed keywords

AMETANTRONE; ANTHRAQUINONE; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); GYRASE INHIBITOR; METHIONINE; METHIONINE MITOXANTRONE AMETANTRONE CONJUGATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL KILLING; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DNA STRAND BREAKAGE; DRUG CONJUGATION; DRUG STRUCTURE; GENE TARGETING; HUMAN; HUMAN TISSUE; IC 50; LEUKEMIA; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTHRAQUINONES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; DNA BREAKS; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HL-60 CELLS; HUMANS; MALE; METHIONINE; MICE; MICE, SCID; MITOXANTRONE; P-GLYCOPROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84862809544     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.01.025     Document Type: Article

References (40)

1. J.C. Wang Cellular roles of DNA topoisomerases: a molecular perspective Nat Rev Mol Cell Biol 3 2002 430 440
2. T.K. Li, and L.F. Liu Tumor cell death induced by topoisomerase-targeting drugs Annu Rev Pharmacol Toxicol 41 2001 53 77
3. J.L. Nitiss DNA topoisomerase II and its growing repertoire of biological functions Nat Rev Cancer 9 2009 327 337
4. L.F. Liu DNA topoisomerase poisons as antitumor drugs Annu Rev Biochem 58 1989 351 375
5. T.K. Li, P.J. Houghton, S.D. Desai, P. Daroui, A.A. Liu, and E.S. Hars Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug Cancer Res 63 2003 8400 8407
6. J.L. Nitiss Targeting DNA topoisomerase II in cancer chemotherapy Nat Rev Cancer 9 2009 338 350
7. A. Bodley, L.F. Liu, M. Israel, R. Seshadri, Y. Koseki, and F.C. Giuliani DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA Cancer Res 49 1989 5969 5978
8. R. Silber, L.F. Liu, M. Israel, A.L. Bodley, Y.H. Hsiang, and S. Kirschenbaum Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase II NCI Monogr 1987 111 115
9. L.F. Liu, T.C. Rowe, L. Yang, K.M. Tewey, and G.L. Chen Cleavage of DNA by mammalian DNA topoisomerase II J Biol Chem 258 1983 15365 15370
10. C.C. Wu, T.K. Li, L. Farh, L.Y. Lin, T.S. Lin, and Y.J. Yu Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide Science 333 2011 459 462
11. N. Zhou, H. Xiao, T.K. Li, E.K.A. Nur, and L.F. Liu DNA damage-mediated apoptosis induced by selenium compounds J Biol Chem 278 2003 29532 29537
12. T.K. Li, A.Y. Chen, C. Yu, Y. Mao, H. Wang, and L.F. Liu Activation of topoisomerase II-mediated excision of chromosomal DNA loops during oxidative stress Genes Dev 13 1999 1553 1560
13. M. Sabourin, and N. Osheroff Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions Nucleic Acids Res 28 2000 1947 1954
14. S.D. Cline, W.R. Jones, M.P. Stone, and N. Osheroff DNA abasic lesions in a different light: solution structure of an endogenous topoisomerase II poison Biochemistry 38 1999 15500 15507
15. R.S. Cvetkovic, and L.J. Scott Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy Drugs 65 2005 1005 1024
16. T. Andoh, and R. Ishida Catalytic inhibitors of DNA topoisomerase II Biochim Biophys Acta 1400 1998 155 171
17. S.E. Lipshultz, N. Rifai, V.M. Dalton, D.E. Levy, L.B. Silverman, and S.R. Lipsitz The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia N Engl J Med 351 2004 145 153
18. J.R. Fan, A.L. Peng, H.C. Chen, S.C. Lo, T.H. Huang, and T.K. Li Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responses DNA Repair (Amst) 7 2008 452 463
19. A.M. Azarova, Y.L. Lyu, C.P. Lin, Y.C. Tsai, J.Y. Lau, and J.C. Wang Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies Proc Natl Acad Sci USA 104 2007 11014 11019
20. U. Kellner, L. Hutchinson, A. Seidel, H. Lage, M.K. Danks, and M. Dietel Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein Int J Cancer 71 1997 817 824
21. K.R. Hande Clinical applications of anticancer drugs targeted to topoisomerase II Biochim Biophys Acta 1400 1998 173 184
22. W.G. Harker, D.L. Slade, R.L. Parr, P.W. Feldhoff, D.M. Sullivan, and M.H. Holguin Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line Cancer Res 55 1995 1707 1716
23. W.G. Harker, D.L. Slade, F.H. Drake, and R.L. Parr Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform Biochemistry 30 1991 9953 9961
24. F. Errington, E. Willmore, M.J. Tilby, L. Li, G. Li, and W. Li Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation Mol Pharmacol 56 1999 1309 1316
25. C.H. Yang, E. Schneider, M.L. Kuo, E.L. Volk, E. Rocchi, and Y.C. Chen BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells Biochem Pharmacol 60 2000 831 837
26. L.A. Doyle, and D.D. Ross Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) Oncogene 22 2003 7340 7358
27. K. Seiter Toxicity of the topoisomerase II inhibitors Expert Opin Drug Saf 4 2005 219 234
28. W.G. Harker, D.L. Slade, R.L. Parr, and M.H. Holguin Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone Cancer Res 55 1995 4962 4971
29. J.E. Gervasoni Jr., S.Z. Fields, S. Krishna, M.A. Baker, M. Rosado, and K. Thuraisamy Subcellular distribution of daunorubicin in P-glycoprotein- positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy Cancer Res 51 1991 4955 4963
30. T.H. Huang, H.C. Chen, S.M. Chou, Y.C. Yang, J.R. Fan, and T.K. Li Cellular processing determinants for the activation of damage signals in response to topoisomerase I-linked DNA breakage Cell Res 20 2010 1060 1075
31. G. Li, H. Mao, X. Ruan, Q. Xu, Y. Gong, and X. Zhang An improved equation and assay for determining the CO(2)/O(2) specificity for Rubisco Photosynth Res 75 2003 287 292
32. Z. Kouchi, T.C. Saido, H. Ohyama, H. Maruta, K. Suzuki, and S. Tanuma The restrictive proteolysis of alpha-fodrin to a 120 kDa fragment is not catalyzed by calpains during thymic apoptosis Apoptosis 2 1997 84 90
33. S.T. Worland, and J.C. Wang Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae J Biol Chem 264 1989 4412 4416
34. L.W. Hsin, H.P. Wang, P.H. Kao, O. Lee, W.R. Chen, and H.W. Chen Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino) anthraquinone-amino acid conjugates Bioorg Med Chem 16 2008 1006 1014
35. C.J. Hsiao, T.K. Li, Y.L. Chan, L.W. Hsin, C.H. Liao, and C.H. Lee WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers Biochem Pharmacol 75 2008 847 856
36. E. Schneider, Y.H. Hsiang, and L.F. Liu DNA topoisomerases as anticancer drug targets Adv Pharmacol 21 1990 149 183
37. W.T. Bellamy P-glycoproteins and multidrug resistance Annu Rev Pharmacol Toxicol 36 1996 161 183
38. L.J. Scott, and D.P. Figgitt Mitoxantrone: a review of its use in multiple sclerosis CNS Drugs 18 2004 379 396
39. J.M. Fortune, and N. Osheroff Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice Prog Nucleic Acid Res Mol Biol 64 2000 221 253
40. I. Laponogov, X.S. Pan, D.A. Veselkov, K.E. McAuley, L.M. Fisher, and M.R. Sanderson Structural basis of gate-DNA breakage and resealing by type II topoisomerases PLoS ONE 5 2010 e11338